PCNAT-01
/ Anda Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 30, 2026
Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy
(clinicaltrials.gov)
- P=N/A | N=0 | Available | Sponsor: Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
New trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • PCNA
1 to 1
Of
1
Go to page
1